PDCD1 and glioblastoma: Another phase I trial (NT03726515) was conducted to evaluate the safety of CAR T-EGFRvIII therapy combined with pembrolizumab (anti-PD-1) in patients with newly diagnosed EGFRvIII+ GBM (Table 3) [85].